With great interest we read the recent publication in Cancer Cell by Taylor et al. 1 who reported on an integrative genomic profiling approach that resulted in the discovery of a previously unrecognized deletion in human prostate cancer encompassing chromosome band 3p14. Found to be associated with the TMPRSS2-ERG fusion, this aberration comprised only eight genes and could be further narrowed down by inspection of additional cases and association with gene expression data to three genes, FOXP1, RYBP and SHQ1.
Interestingly, we recently have reported a recurrent microdeletion in the respective chromosomal region on 3p14 in cytogenetically normal acute myeloid leukemia.
2 Using high-resolution single-nucleotide polymorphism microarray profiling and subsequent fluorescence in situ hybridization, we Letters to the Editor could delineate a minimally altered 2 Mb sized region in 3p14.1-p13, which contained eight genes (FOXP1, GPR27, PROK2, EIFE3, RYBP, SHQ1, GLT8D4 and PPP4R2; Figure 1a ; hg19). This cryptic deletion in band 3p14.1-p13 also overlapped with 3p deletions, previously described in a cohort of AML cases with complex karyotypes. 3 In accordance to the findings by Taylor et al. 1 in prostate cancer, parallel analysis of gene expression showed a marked downregulation of the deleted genes with the most pronounced gene dosage effects for RYBP (Ring and YY1 binding protein) and SHQ1 (Figure 1b) , and none of the 3p deleted cases harbored FOXP1 mutations in the remaining allele (unpublished data). Furthermore, supervised analysis comparing the 3p14.1-p13 deleted cases with other cytogenetically normal acute myeloid leukemias showed a characteristic gene expression profile, thereby further pointing to a distinct biology underlying these cases.
The 3p deletion-associated gene expression pattern was significantly enriched for genes belonging to the Biocarta pathways associated with polycomb gene function (the PRC2 (polycomb repressive complex 2) pathway) and the p53 signaling pathway (Figure 1c ), which fits well with the facts that RYBP encodes a polycomb group transcriptional repressor and has been implicated in inhibition of MDM2 and subsequent p53 stabilization. 4 In addition, we observed an enrichment of genes involved in ribosomal biogenesis ('tumor suppressor Arf inhibits ribosomal biogenesis') and telomere regulation ('overview of telomerase protein component gene hTert transcriptional regulation' and 'telomeres, telomerase, cellular aging and immortality'; Figure 1c ). Here, it is of note that SHQ1 codes for an essential protein necessary for stable expression of box H/ACA small nucleolar ribonucleoproteins, which are essential for ribosome biogenesis and telomerase stability. Thus, our previously reported 3p14. Lenalidomide is an immunomodulatory drug related to thalidomide that has recently been reported to have significant single-agent activity in relapsed chronic lymphocytic leukemia (CLL), with response rates of 35-50% including some complete responses. 1, 2 The mechanism of action is unknown, but appears to be immune-mediated given that lenalidomide alters cytokine levels and stimulates T-and natural killer-cell function and lacks cytotoxicity against CLL in vitro. 3 In CLL patients, the administration of lenalidomide can be associated with tumor flare, a syndrome of painful enlarging lymphadenopathy, increased white count, fever and rash. 1, 2 This tumor flare can potentially escalate to become life-threatening, with renal insufficiency, tumor lysis or a systemic inflammatory response. 4, 5 The mechanism of tumor flare remains unknown.
Given the high reported response rates with lenalidomide and its theoretical potential to help preserve immune function, we undertook this phase I study of lenalidomide in combination with fludarabine rituximab to determine the maximum tolerated dose of lenalidomide in combination with fludarabine rituximab, as well as to assess any preliminary signs of efficacy. This prospective study enrolled patients with previously untreated CLL/small lymphocytic lymphoma who required therapy based on the 1996 NCI WG criteria. Adequate organ function was required and was defined as ANC 41000/ml, platelets 450 000/ml, creatinine p1.5 mg/dl and total bilirubin p1.5 mg/dl. All patients tested negative for hepatitis B and C, and none had autoimmune hemolytic anemia. The study was approved by the Dana-Farber Harvard Cancer Center Institutional Review Board, and all patients signed informed consent before the initiation of the therapy.
In total, six cycles of combination therapy followed by two cycles of consolidation lenalidomide were originally planned. Fludarabine was given at the standard dose of 25 mg/m 2 intravenously (i.v.) for 3-5 days depending on the dose level, with rituximab 375 mg/m 2 on day 1 of each 28-day cycle. In order to minimize the infusion reactions in the first cycle, all patients received a split dose of rituximab, with 50 mg/m 2 on day 1 followed by 325 mg/m 2 on day 3. The lenalidomide dosing began at 2.5 mg daily for days 1-21 of a 28-day cycle. The plan was to start at dose level 1, with 3 days of fludarabine and 2.5 mg lenalidomide per day, with the lenalidomide dose levels subsequently being increased to 5 mg and then 10 mg, followed by the addition of fludarabine on days 4-5 and ultimately by escalation of the lenalidomide from 10 to 25 mg in 5-mg increments. De-escalation from dose level 1 decreased the lenalidomide dose to 2.5 mg every other day in dose level-1 and then decreased the fludarabine dose to 2 days in dose level-2. All patients received infectious prophylaxis with trimethoprimsulfamethoxazole and acyclovir (or equivalent). For prevention of deep venous thrombosis, aspirin 81 mg daily was given to patients with platelet counts over 50 000/ml. During the first cycle of therapy, all patients received allopurinol and i.v. hydration with therapy; chemistries including a full comprehensive panel, calcium, phosphate, uric acid and lactate dehydrogenase were checked 2-3 times per week and additional i.v. hydration provided at that time if needed. Tumor flare was treated with ibuprofen, oxycodone and/or glucocorticoids (a Medrol pak).
The study used a standard 3 þ 3 dose escalation design, with dose limiting toxicity (DLT) assessed in the first 28-day cycle only. DLT was defined as grade 3 or greater non-hematological toxicity (except grade 4 for allergic reactions), grade 4 neutropenia or thrombocytopenia, grade 3 febrile neutropenia, or a 42-week treatment delay in initiation of cycle 2. Hematological toxicity was assessed according to the NCI-WG 1996 criteria, while non-hematological toxicity was assessed according to the Common Terminology Criteria for Adverse Events v3.0.
Nine patients were enrolled on this study, as detailed in Table 1 . The median age was 59 years, with a median time from
